Jan 5 (Reuters) - Prima Biomed Ltd PRR.AX
* Asx alert-prima enters new mta with cytlimic-prr.ax
* Under agreement Prima will provide imp321 for formulation development targeting new pre-clinical and clinical development study to be conducted by CYTLIMIC
* Has entered into a new collaboration agreement with Japan's CYTLIMIC
* Development will be funded by CYTLIMIC and MTA will be revenue generating for Prima Source text for Eikon: ID:nASX5vkjjy Further company coverage: PRR.AX